CPE News (2/23/2021) – Nurosene Inc. has filed a preliminary prospectus for a proposed initial public offering of up to 8,888,888 common shares at a price of $0.90 per share for gross proceeds of up to $8,000,000.
Canaccord Genuity Corp. and Beacon Securities Limited act as offering underwriters. DLA Piper (Canada) LLP and Burstall LLP act as legal counsel to Nurosens and the underwriters respectively.
Nurosene has applied to the CSE for the listing of its common shares under the symbol “MEND.”
Nurosene currently has 22,425,475 common shares issued and outstanding, with an implied non-dilutive pre-IPO valuation of $22.2 million at the offering price.
Nurosene has been backed by private investors since its inception. There is no shareholder or entity holding 10% or more of the outstanding common shares.
Nurosene Inc. is a technology-driven wellness company focused on implementing healthy habits designed to align the mind, body and brain for daily mental wellness and overall brain health. Nurosene will be launching its Mobile Application which provides users with personalized habit-forming strategies along with a line of proprietary nutraceutical supplements which have been formulated to target specific cell structures and their inherent functions.
photo credit: Nurosene